$2.41-0.04 (-1.63%)
Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally.
Intelligent Bio Solutions Inc. in the Healthcare sector is trading at $2.41. The stock is currently near its 52-week low of $2.29, remaining 73.7% below its 200-day moving average. Technical signals show neutral RSI of 48 and bullish MACD crossover, explaining why INBS maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelli...
Intelligent Bio Solutions (INBS) reported late Wednesday an agreement with two healthcare-focused in
td class="col-issue">New Era Energy & Digital Inc.
NasdaqCM:INBS 1 Year Share Price vs Fair Value Explore Intelligent Bio Solutions's Fair Values from the Community and...
Intelligent Bio Solutions Inc. (NASDAQ:INBS) reported preliminary fiscal fourth quarter revenue results and selected operational highlights on Thursday. Intelligent Bio Solutions is a medical technology company delivering intelligent, rapid, noninvasive testing solutions. “Fiscal 2025 represented a year of disciplined execution and strategic investment. For the fiscal fourth quarter, we expect to report another quarter of sequential and year-over-year revenue growth,” said Harry Simeonidis, Pres
Intelligent Bio Solutions Inc. (NASDAQ:INBS) on Wednesday announced the collection of new data that further reinforces the security and performance of its Intelligent Fingerprinting Drug Screening System, strengthening its FDA 510(k) submission. "We are planning to submit our findings to the FDA in August, along with the new data collected," said Peter Passaris, Vice President of Product Development. The company completed cybersecurity testing, including penetration testing and electromagnetic c